MINIPRESS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Minipress, and what generic alternatives are available?
Minipress is a drug marketed by Pfizer and is included in two NDAs.
The generic ingredient in MINIPRESS is prazosin hydrochloride. There are seventeen drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the prazosin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Minipress
A generic version of MINIPRESS was approved as prazosin hydrochloride by TEVA PHARMS on September 12th, 1988.
Summary for MINIPRESS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 4 |
| Raw Ingredient (Bulk) Api Vendors: | 117 |
| Clinical Trials: | 27 |
| Patent Applications: | 1,782 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for MINIPRESS |
| What excipients (inactive ingredients) are in MINIPRESS? | MINIPRESS excipients list |
| DailyMed Link: | MINIPRESS at DailyMed |
Recent Clinical Trials for MINIPRESS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Yale University | Phase 1/Phase 2 |
| University of Washington | Phase 4 |
| Fast Grants | Phase 2 |
Pharmacology for MINIPRESS
| Drug Class | alpha-Adrenergic Blocker |
| Mechanism of Action | Adrenergic alpha-Antagonists |
Anatomical Therapeutic Chemical (ATC) Classes for MINIPRESS
US Patents and Regulatory Information for MINIPRESS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | MINIPRESS | prazosin hydrochloride | CAPSULE;ORAL | 017442-002 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-001 | Jan 29, 1992 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Pfizer | MINIPRESS | prazosin hydrochloride | CAPSULE;ORAL | 017442-003 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Pfizer | MINIPRESS | prazosin hydrochloride | CAPSULE;ORAL | 017442-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
| Pfizer | MINIPRESS XL | prazosin hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019775-002 | Jan 29, 1992 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MINIPRESS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pfizer | MINIPRESS | prazosin hydrochloride | CAPSULE;ORAL | 017442-002 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Pfizer | MINIPRESS | prazosin hydrochloride | CAPSULE;ORAL | 017442-002 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Pfizer | MINIPRESS | prazosin hydrochloride | CAPSULE;ORAL | 017442-003 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Pfizer | MINIPRESS | prazosin hydrochloride | CAPSULE;ORAL | 017442-002 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Pfizer | MINIPRESS | prazosin hydrochloride | CAPSULE;ORAL | 017442-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Pfizer | MINIPRESS | prazosin hydrochloride | CAPSULE;ORAL | 017442-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| Pfizer | MINIPRESS | prazosin hydrochloride | CAPSULE;ORAL | 017442-003 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MINIPRESS
See the table below for patents covering MINIPRESS around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Malaysia | 8100271 | NOVEL CRYSTALLINE FORMS OF PRAZOSIN HYDROCHLORIDE | ⤷ Try a Trial |
| Hungary | 173641 | PROCESS FOR PRODUCING CRISTALLINE PRAZOSIN-HYDROCHLORIDES | ⤷ Try a Trial |
| Norway | 770674 | ⤷ Try a Trial | |
| Denmark | 86877 | ⤷ Try a Trial | |
| Philippines | 13965 | METHODS FOR TREATING CONGESTIVE HEART FAILURE AND ISCHEMIC HEART DISEASE | ⤷ Try a Trial |
| Spain | 8707447 | ⤷ Try a Trial | |
| New Zealand | 183450 | PREPARATION OF THE CRYSTALLINE -FORM OF 2-(4-(2-FOROYL)-PIPERAZIN-1-YL)-4-AMINO-6,7-DIMETHOXY-QUINAZDINE HYDROCHLORIDE | ⤷ Try a Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
